Skip to main content
. Author manuscript; available in PMC: 2019 May 8.
Published in final edited form as: Crit Care Med. 2016 Apr;44(4):671–679. doi: 10.1097/CCM.0000000000001465

Table 2.

Management and Outcomes of S. aureus bacteremia by Day 4 Outcome

Characteristic Resolving SAB (n=149) Persistent SAB (n=47) P value
Management
Received ID consult a 77 (52%) 34 (72%) 0.02
Time to receive consultation (days) b, c 2 (1,4) 1 (1,2) 0.05
Consult received prior to day 4 a, b 67 (87%) 29 (85%) 0.77
Time to receipt of effective Anti-SA therapy (days) c 0 (0, 1) 0 (0, 1) 0.16
Empiric Antibiotic therapy a
Vancomycin 122 (82%) 33 (70%) 0.10
Other anti-Staphylococcal 27 (18%)f 14 (30%)g 0.10
Hardware Removed a, d 34 (85%) 9 (90%) 1.00
Time to Hardware removal (days) c, d 2 (1, 3.75) 4 (2.5, 5) 0.06
Outcomes
30-day mortality a 7 (5%) 13 (28%) <0.0001
30-day recurrence a, e 8 (6%) 1 (3%) 1.00
Length of hospital stay (days)c, e 10 (6, 17) 16.5 (10.8,25) 0.01

Abbreviations: ID, Infectious diseases; SA, S. aureus; MRSA, Methicillin-resistant S. aureus; MSSA, Methicillin-susceptible S. aureus;

a

Chi- squared test;

b

Of those who received ID consult;

c

median (IQR) reported, Wilcoxon rank sum test;

d

Of those with infected hardware (n=40, n=10);

e

Calculated from surviving patients only;

f

linezolid, clindamycin, trimethoprim/sulfamethoxazole, daptomycin, ceftriaxone, oxacillin, cefazolin, other;

g

clindaymycin, linezolid, daptomycin, ceftriaxone, cefazolin